The ORVAC Trial: A Phase IV, Double-blind, Randomised, Placebo-controlled Clinical Trial of a Third Scheduled Dose of RV1 Rotavirus Vaccine in Australian Indigenous Infants to Improve Protection Against Gastroenteritis
Latest Information Update: 12 Mar 2024
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ORVAC
- 05 Mar 2024 Planned End Date changed from 1 Dec 2020 to 1 Dec 2026.
- 05 Mar 2024 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2026.
- 05 Mar 2024 Status changed from recruiting to active, no longer recruiting.